Oncology Biomarkers

High levels of integrin beta-6 (IB6) in metastatic non-small cell lung cancer suggest that it could be a target for treatment.

New research highlights DR-70 as a promising noninvasive biomarker for diagnosing and staging bladder cancer, potentially improving early detection strategies.

A study reveals circulating tumor cells (CTCs) as potential biomarkers for predicting aggressive DCIS, aiming to reduce overtreatment and improve patient outcomes.

Next-generation sequencing (NGS) holds great promise for identifying 'tumor-agnostic' therapies, but evidence does not support its routine use in clinical care and diagnosis of sarcoma, a consensus statement concludes.

Biomarkers are pivotal for confirming diagnoses, predicting disease progression, and tailoring therapeutic modalities. Recent research focuses on the ‘omics’ technologies —genomics, proteomics, metabolomics.

Promoting interdisciplinary collaboration via molecular tumor boards and shared decision-making frameworks might improve the precision and applicability of testing in clinical settings, according to a set of new Academy of Managed Care Pharmacy recommendations.

Many potential colorectal biomarkers are only studied once.